CYTX Profile — Plus Therapeutics Inc
Cytori Therapeutics develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Co.'s drug candidates at its Cytori Nanomedicine platform include: ATI-0918, which is its primary drug candidate and a generic version of pegylated liposomal encapsulated doxorubicin; and ATI-1123, a chemical entity which is a nanoparticle-encapsulated form of docetaxel, also a workhorse chemotherapeutic drug used for various cancers. Co.'s product candidates at its Cytori Cell Therapy platform include Habeo Cell Therapy, which is its primary product candidate for the treatment of impaired hand function in patients with scleroderma.